Exact Sciences: Shareholder Approval Clears Final Hurdle, Now Watch the Clock

The final shareholder hurdle has been cleared. Exact Sciences stockholders overwhelmingly approved the Abbott acquisition at a special meeting held earlier this week, with preliminary results showing more than 99% of votes cast in favor. This decisive vote removes a major overhang and sets the stage for the deal to close.

The key implication is a clear timeline. Subject to regulatory approvals, the transaction is now expected to close before the end of the second calendar quarter of 2026. More importantly, the $105 per share cash offer has become the primary valuation anchor for the stock. As analyst commentary shows, firms are recalibrating models around this agreed price, with many lifting targets to $105 and downgrading ratings to reflect the limited upside from here. The deal's fate now hinges on the regulatory clock.

The Setup: Deal Terms and Remaining Hurdles

The financial terms are now set. The deal is valued at approximately $21 billion in equity, with Exact Sciences shareholders receiving $105 per share in cash. Under the merger agreement, Exact Sciences will merge with a subsidiary of Abbott Laboratories and become a wholly owned subsidiary of the medical device giant. This structure is straightforward, but the immediate financial impact is what matters most for the stock.

Abbott has framed the acquisition as a strategic fit, but the key takeaway for investors is the promised accretion. The company states the deal will be immediately accretive to Abbott's revenue growth and gross margin. This claim is central to the transaction's logic; it suggests the purchase price is justified by the target's cash-generating ability and its ability to boost Abbott's financial profile from day one.

With shareholder approval complete, the final hurdles are regulatory. Completion remains subject to customary closing conditions, including regulatory approvals. This is the standard antitrust and competition review process. The clock is now ticking toward the second quarter of 2026, but any regulatory delay or condition could push the close later. For Exact Sciences, the setup is clear: the deal is on track, the price is locked, and the stock's path forward is now tied entirely to the regulatory outcome.

The Trade: Valuation and Near-Term Catalysts

The market has recalibrated. With the deal price locked in, analyst models are now explicitly anchored to the $105 offer. This shift is clear in the numbers: revenue growth assumptions for Exact Sciences have been lowered as analysts frame their projections around the agreed transaction, moving from 12.30% to 11.03%. Yet, the net profit margin outlook has been viewed more favorably, reflecting the deal's immediate accretion to Abbott's financials. The result is a stable fair value estimate, with one platform showing $105.81 per share as the current benchmark. For investors, this means the stock's trajectory is now binary: it trades near the offer price, with limited upside from standalone growth assumptions.

The key near-term catalyst is regulatory clearance. The deal's closing target of before the end of the second calendar quarter of 2026 is now the critical timeline. The resolution of antitrust and competition reviews will determine if that target is met. Analyst commentary suggests this is a low-risk step, with firms like Citi noting limited concern about antitrust or regulatory issues. The setup is straightforward: clearance by mid-year means a clean close at $105. Any delay, however, would extend the timeline and keep the stock in a holding pattern.

The primary risk is regulatory friction. While conditions are expected to be met, any requirement for divestitures or structural changes could alter the deal's economics or push the close later. The shareholder vote removed a major overhang, but the regulatory clock remains the final hurdle. For traders, the trade is clear: the stock is a waiting game for the Q2 closing. The valuation is set, the path is defined, and the only variable left is the outcome of the regulatory review.